| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 2500- | meben, | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA |
| 1782- | MEL, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 971- | MEL, | Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP |
| 2376- | MET, | Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway |
| - | in-vitro, | Nor, | NA |
| 2375- | MET, | Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling |
| - | in-vitro, | GC, | SGC-7901 |
| 2371- | MET, | The role of pyruvate kinase M2 in anticancer therapeutic treatments |
| - | Review, | Var, | NA |
| 2378- | MET, | Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway |
| - | in-vitro, | SCC, | CAL27 | - | in-vivo, | NA, | NA |
| 2386- | MET, | Mechanisms of metformin inhibiting cancer invasion and migration |
| - | Review, | Var, | NA |
| 1066- | MET, | Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma |
| - | in-vitro, | SCC, | NA |
| 970- | MET, | Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer |
| 2487- | metroC, | Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2245- | MF, | Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis |
| - | in-vitro, | Nor, | NIH-3T3 |
| 4110- | MF, | Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia |
| - | Review, | Stroke, | NA |
| 3479- | MF, | Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies |
| - | Review, | NA, | NA |
| 3476- | MF, | Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation |
| - | in-vitro, | Stroke, | 1321N1 | - | in-vitro, | Park, | NA |
| 3482- | MF, | Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice |
| - | in-vitro, | NA, | NA |
| 1203- | MSM, | Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 1270- | NCL, | Rad, | Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells |
| - | in-vivo, | Lung, | NA |
| 968- | OA, | Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MBT-2 |
| 4643- | OLE, | HT, | Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine |
| - | Review, | Var, | NA |
| 1812- | Oxy, | Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA | - | in-vitro, | NA, | BEAS-2B |
| 1813- | Oxy, | Advances in hyperbaric oxygen to promote immunotherapy through modulation of the tumor microenvironment |
| - | Review, | Var, | NA |
| 2396- | PACs, | PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma |
| - | in-vitro, | HCC, | HCCLM3 | - | in-vitro, | HCC, | SMMC-7721 cell | - | in-vitro, | HCC, | Bel-7402 | - | in-vitro, | HCC, | HUH7 | - | in-vitro, | HCC, | HepG2 | - | in-vitro, | Nor, | L02 |
| 959- | PACs, | Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | BC, | MDA-MB-231 |
| 3259- | PBG, | Propolis and its therapeutic effects on renal diseases: A review |
| - | Review, | Nor, | NA |
| 1662- | PBG, | The immunomodulatory and anticancer properties of propolis |
| - | Review, | Var, | NA |
| 1666- | PBG, | Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer |
| - | Review, | Var, | NA |
| 1668- | PBG, | Propolis: A Detailed Insight of Its Anticancer Molecular Mechanisms |
| - | Review, | Var, | NA |
| 2380- | PBG, | Potential Strategies for Overcoming Drug Resistance Pathways Using Propolis and Its Polyphenolic/Flavonoid Compounds in Combination with Chemotherapy and Radiotherapy |
| - | Review, | Var, | NA |
| 4930- | PEITC, | Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy |
| - | vitro+vivo, | Lung, | A549 |
| 4922- | PEITC, | Phenethyl Isothiocyanate: A comprehensive review of anti-cancer mechanisms |
| - | Review, | Var, | NA |
| 4918- | PEITC, | Nutritional Sources and Anticancer Potential of Phenethyl Isothiocyanate: Molecular Mechanisms and Therapeutic Insights |
| - | Review, | Var, | NA |
| 4936- | PEITC, | PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth |
| - | in-vivo, | BC, | MDA-MB-231 |
| 4941- | PEITC, | PEITC: A resounding molecule averts metastasis in breast cancer cells in vitro by regulating PKCδ/Aurora A interplay |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2999- | PL, | Piperlongumine alleviates corneal allograft rejection via suppressing angiogenesis and inflammation |
| - | in-vivo, | Nor, | HUVECs |
| 2953- | PL, | Piperlongumine Acts as an Immunosuppressant by Exerting Prooxidative Effects in Human T Cells Resulting in Diminished TH17 but Enhanced Treg Differentiation |
| - | in-vitro, | Nor, | NA |
| 2300- | QC, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 3353- | QC, | Quercetin triggers cell apoptosis-associated ROS-mediated cell death and induces S and G2/M-phase cell cycle arrest in KON oral cancer cells |
| - | in-vitro, | Oral, | KON | - | in-vitro, | Nor, | MRC-5 |
| 3368- | QC, | The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update |
| - | Review, | Var, | NA |
| 76- | QC, | Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy |
| - | in-vitro, | Pca, | PC3 |
| 910- | QC, | The Anti-Cancer Effect of Quercetin: Molecular Implications in Cancer Metabolism |
| 2332- | RES, | Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism |
| - | Review, | Var, | NA |
| 2687- | RES, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | NA, | NA | - | Review, | AD, | NA |
| 2471- | RES, | Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression |
| - | in-vivo, | Diabetic, | NA |
| 3082- | RES, | Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vivo, | NA, | NA |
| 3081- | RES, | Resveratrol and p53: How are they involved in CRC plasticity and apoptosis? |
| - | Review, | CRC, | NA |
| 3080- | RES, | Resveratrol: A miraculous natural compound for diseases treatment |
| - | Review, | Var, | NA |
| 3078- | RES, | The Effects of Resveratrol on Prostate Cancer through Targeting the Tumor Microenvironment |
| - | Review, | Pca, | NA |
| 3076- | RES, | Resveratrol for targeting the tumor microenvironment and its interactions with cancer cells |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:143 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid